Literature DB >> 15178557

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.

Geneviève Dubuc1, Ann Chamberland, Hanny Wassef, Jean Davignon, Nabil G Seidah, Lise Bernier, Annik Prat.   

Abstract

OBJECTIVE: Neural apoptosis-regulated convertase (NARC)-1 is the newest member of the proprotein convertase family implicated in the cleavage of a variety of protein precursors. The NARC-1 gene, PCSK9, has been identified recently as the third locus implicated in autosomal dominant hypercholesterolemia (ADH). The 2 other known genes implicated in ADH encode the low-density lipoprotein receptor and apolipoprotein B. As an approach toward the elucidation of the physiological role(s) of NARC-1, we studied its transcriptional regulation. METHODS AND
RESULTS: Using quantitative RT-PCR, we assessed NARC-1 regulation under conditions known to regulate genes involved in cholesterol metabolism in HepG2 cells and in human primary hepatocytes. We found that NARC-1 expression was strongly induced by statins in a dose-dependent manner and that this induction was efficiently reversed by mevalonate. NARC-1 mRNA level was increased by cholesterol depletion but insensitive to liver X receptor activation. Human, mouse, and rat PCSK9 promoters contain 2 typical conserved motifs for cholesterol regulation: a sterol regulatory element (SRE) and an Sp1 site.
CONCLUSIONS: PCSK9 regulation is typical of that of the genes implicated in lipoprotein metabolism. In vivo, PCSK9 is probably a target of SRE-binding protein (SREBP)-2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15178557     DOI: 10.1161/01.ATV.0000134621.14315.43

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  192 in total

1.  PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.

Authors:  Estelle Rousselet; Jadwiga Marcinkiewicz; Jasna Kriz; Ann Zhou; Mary E Hatten; Annik Prat; Nabil G Seidah
Journal:  J Lipid Res       Date:  2011-04-25       Impact factor: 5.922

2.  PCSK9 as a therapeutic target in atherosclerosis.

Authors:  Ali J Marian
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

3.  MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis.

Authors:  M Lucrecia Alvarez; Mahdieh Khosroheidari; Elena Eddy; Stefania C Done
Journal:  Atherosclerosis       Date:  2015-08-20       Impact factor: 5.162

4.  Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.

Authors:  Yajun Duan; Yuanli Chen; Wenquan Hu; Xiaoju Li; Xiaoxiao Yang; Xin Zhou; Zhinan Yin; Deling Kong; Zhi Yao; David P Hajjar; Lin Liu; Qiang Liu; Jihong Han
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

5.  E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver.

Authors:  Qiuwen Lai; Albert Giralt; Cédric Le May; Lianjun Zhang; Bertrand Cariou; Pierre-Damien Denechaud; Lluis Fajas
Journal:  JCI Insight       Date:  2017-05-18

Review 6.  Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.

Authors:  Davide Noto; Angelo B Cefalù; Maurizio R Averna
Journal:  Curr Atheroscler Rep       Date:  2014-06       Impact factor: 5.113

7.  Isolation and characterization of the circulating truncated form of PCSK9.

Authors:  Bomie Han; Patrick I Eacho; Michael D Knierman; Jason S Troutt; Robert J Konrad; Xiaohong Yu; Krista M Schroeder
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

8.  A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes.

Authors:  Jiayin Yang; Lai-Yung Wong; Xiao-Yu Tian; Rui Wei; Wing-Hon Lai; Ka-Wing Au; Zhiwei Luo; Carl Ward; Wai-In Ho; David P Ibañez; Hao Liu; Xichen Bao; Baoming Qin; Yu Huang; Miguel A Esteban; Hung-Fat Tse
Journal:  J Vis Exp       Date:  2018-09-15       Impact factor: 1.355

9.  Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.

Authors:  Susan G Lakoski; Fang Xu; Gloria L Vega; Scott M Grundy; Manisha Chandalia; Chun Lam; Robert S Lowe; Michael E Stepanavage; Thomas A Musliner; Jonathan C Cohen; Helen H Hobbs
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

Review 10.  Dynamics of hepatic and intestinal cholesterol and bile acid pathways: The impact of the animal model of estrogen deficiency and exercise training.

Authors:  Jean-Marc Lavoie
Journal:  World J Hepatol       Date:  2016-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.